(image: Korea Bizwire)
SEOUL, Aug. 14 (Korea Bizwire) — South Korean pharmaceutical companies, currently involved in developing drugs for diabetes and obesity, are emphasizing the improvement of usage convenience by extending drug efficacy durations and modifying formulations.
Peptron Inc. is progressing toward transferring PT404, a sustained-release diabetes and obesity treatment formulation, to global pharmaceutical firms.
Unlike existing treatments for diabetes and obesity that require weekly administration, PT404 can maintain its medical effectiveness for an entire month with just a single injection.
Inventage Lab Inc. is developing two treatments for diabetes and obesity, namely IVL3021 and IVL3005, aiming to sustain medical efficacy for over a month with a single use.
According to the company, IVL3021 releases the medical substance for one month under nonclinical conditions, while IVL3005 extends this to two months.
Meanwhile, Hanmi Pharm Co. is presently involved in creating an obesity treatment using Lapscovery, its independently developed platform technology.
The technology reduces injection frequency and quantity by prolonging the half-life of biopharmaceuticals.
Lapscovery can elongate the in-body durability of biopharmaceuticals up to one month when administered once, thereby decreasing injection frequency and minimizing side effects.
J. S. Shin (js_shin@koreabizwire.com)
